[A19-86] Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2020
Project no.:
A19-86
Commission:
Commission awarded on 07.10.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of adult patients with extensive-stage small cell lung cancer
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.